|
|
|
Volumn 61, Issue 1, 2006, Pages
|
|
The unfinished business of U.S. drug safety regulation
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDEPRESSANT AGENT;
ASTEMIZOLE;
BROMFENAC;
CISAPRIDE;
CYCLOOXYGENASE 2 INHIBITOR;
DURACET;
ERYTHROMYCIN;
HYPOCHOLESTEROLEMIC AGENT;
TERFENADINE;
TROGLITAZONE;
TROVAFLOXACIN;
CARDIOTOXICITY;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG LABELING;
DRUG LEGISLATION;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG PROGRAM;
DRUG SAFETY;
DRUG SCREENING;
DRUG SURVEILLANCE PROGRAM;
DRUG USE;
FOOD AND DRUG ADMINISTRATION;
FUNDING;
HEALTH CARE ORGANIZATION;
HEALTH CARE SYSTEM;
HEALTH INSURANCE;
HEART ARRHYTHMIA;
HORMONE SUBSTITUTION;
HUMAN;
KIDNEY FAILURE;
LAW SUIT;
LIVER TOXICITY;
MALPRACTICE;
MEDICAL INFORMATION SYSTEM;
PATIENT COMPLIANCE;
POSTMARKETING SURVEILLANCE;
PRESCRIPTION;
REVIEW;
RHABDOMYOLYSIS;
RISK ASSESSMENT;
RISK FACTOR;
RISK MANAGEMENT;
SIDE EFFECT;
STANDARDIZATION;
SUICIDE;
UNITED STATES;
CLINICAL COMPETENCE;
COST SHARING;
DRUG APPROVAL;
DRUG EVALUATION, PRECLINICAL;
DRUG INDUSTRY;
GUIDELINE ADHERENCE;
HUMANS;
INSURANCE COVERAGE;
INSURANCE POOLS;
PRODUCT SURVEILLANCE, POSTMARKETING;
RISK MANAGEMENT;
SAFETY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 33645834967
PISSN: 1064590X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (11)
|
|
References (0)
|
